) today announced that the U.S. Food and Drug Administration (FDA) has approved BYDUREON™ (exenatide extended-release for injectable suspension) – the first once-weekly treatment for type 2 diabetes.

Appointment comes as Vivani prioritizes the development of its GLP-1 implants for the treatment of obesity and chronic weight management Under Bradbury’s leadership as CEO, Amylin Pharmaceuticals, ...

Wednesday, Vivani Medical Inc (NASDAQ:VANI) released preclinical data on weight loss effects for NPM-115, the company’s miniature, twice-yearly exenatide subdermal implant under development for ...